Fisher Asset Management LLC Buys 694,585 Shares of Boston Scientific Co. (NYSE:BSX)

Fisher Asset Management LLC raised its position in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 17.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 4,771,935 shares of the medical equipment provider's stock after acquiring an additional 694,585 shares during the period. Fisher Asset Management LLC owned approximately 0.32% of Boston Scientific worth $399,888,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in BSX. Advisors Asset Management Inc. boosted its position in shares of Boston Scientific by 45.6% in the first quarter. Advisors Asset Management Inc. now owns 7,544 shares of the medical equipment provider's stock worth $517,000 after buying an additional 2,361 shares during the period. Silvercrest Asset Management Group LLC boosted its holdings in Boston Scientific by 28.1% in the first quarter. Silvercrest Asset Management Group LLC now owns 50,808 shares of the medical equipment provider's stock valued at $3,480,000 after purchasing an additional 11,138 shares during the last quarter. Kennedy Capital Management LLC purchased a new position in Boston Scientific in the first quarter valued at about $3,021,000. B. Riley Wealth Advisors Inc. boosted its holdings in Boston Scientific by 52.0% in the first quarter. B. Riley Wealth Advisors Inc. now owns 16,270 shares of the medical equipment provider's stock valued at $1,114,000 after purchasing an additional 5,564 shares during the last quarter. Finally, Meiji Yasuda Life Insurance Co boosted its holdings in Boston Scientific by 49.6% in the first quarter. Meiji Yasuda Life Insurance Co now owns 68,568 shares of the medical equipment provider's stock valued at $4,696,000 after purchasing an additional 22,725 shares during the last quarter. Hedge funds and other institutional investors own 89.07% of the company's stock.

Boston Scientific Price Performance

Shares of BSX traded down $0.75 during trading hours on Monday, hitting $89.25. 10,227,334 shares of the company were exchanged, compared to its average volume of 6,096,185. The company has a market capitalization of $131.53 billion, a PE ratio of 73.76, a PEG ratio of 2.65 and a beta of 0.79. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.48 and a quick ratio of 1.02. The firm has a fifty day simple moving average of $86.11 and a 200-day simple moving average of $80.32. Boston Scientific Co. has a one year low of $53.93 and a one year high of $91.93.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings data on Wednesday, October 23rd. The medical equipment provider reported $0.63 earnings per share for the quarter, topping the consensus estimate of $0.59 by $0.04. The business had revenue of $4.21 billion during the quarter, compared to analyst estimates of $4.04 billion. Boston Scientific had a return on equity of 17.23% and a net margin of 11.26%. The company's revenue was up 19.3% compared to the same quarter last year. During the same period last year, the company posted $0.50 EPS. As a group, sell-side analysts predict that Boston Scientific Co. will post 2.46 earnings per share for the current year.

Insider Transactions at Boston Scientific

In other news, Director Edward J. Ludwig sold 4,877 shares of the stock in a transaction on Thursday, November 21st. The stock was sold at an average price of $91.63, for a total value of $446,879.51. Following the completion of the sale, the director now owns 39,398 shares in the company, valued at $3,610,038.74. This represents a 11.02 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Michael F. Mahoney sold 162,777 shares of the stock in a transaction on Monday, October 7th. The stock was sold at an average price of $84.63, for a total value of $13,775,817.51. Following the sale, the chief executive officer now owns 1,572,096 shares of the company's stock, valued at approximately $133,046,484.48. This represents a 9.38 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 328,157 shares of company stock valued at $27,894,270 in the last three months. 0.50% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research analysts recently commented on BSX shares. Mizuho increased their price target on Boston Scientific from $100.00 to $110.00 and gave the company an "outperform" rating in a report on Thursday, October 24th. Wells Fargo & Company upped their price objective on Boston Scientific from $87.00 to $98.00 and gave the company an "overweight" rating in a research note on Thursday, October 24th. Evercore ISI upped their price objective on Boston Scientific from $82.00 to $90.00 and gave the company an "outperform" rating in a research note on Tuesday, October 1st. TD Cowen upped their price objective on Boston Scientific from $86.00 to $100.00 and gave the company a "buy" rating in a research note on Monday, October 21st. Finally, Truist Financial increased their price target on Boston Scientific from $90.00 to $100.00 and gave the stock a "buy" rating in a research report on Monday, October 14th. Four investment analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Boston Scientific has a consensus rating of "Moderate Buy" and an average price target of $93.39.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.